China-Pak Strategic Partnership Brings CAR-T Therapy to Pakistan
— October 22, 2024
BEIJING (AIA) Beijing Yuanxin Huibao Technology Co., Ltd., the Pakistan China Business Association, and Nanjing IASO Biotechnology Co., Ltd. have signed a strategic cooperation agreement to promote chimeric antigen receptor T-cell (CAR-T) therapy for adult patients with multiple myeloma in Pakistan.
The agreement, signed in Beijing last week, aims to increase the accessibility of CAR-T therapy, offering new hope to Pakistani patients. According to a report by China Economic Net (CEN) on Tuesday, the collaboration also seeks to introduce innovative payment models to ease financial pressures and improve drug access.
Tahir Farooq, President of the Pakistan China Business Association, highlighted the significance of this partnership in bringing advanced medical therapies to Pakistan. “This agreement will not only introduce CAR-T therapy but will also alleviate the financial burden on patients,” Farooq said.
Eric Tian, Head of Overseas Operations at IASO Biotechnology, noted that the partnership would combine the expertise of all parties involved to enhance the development of innovative treatment solutions, offering more efficient CAR-T services for Pakistani patients.
CAR-T therapy is considered a breakthrough in cell therapy, especially for treating haematological cancers.
Peng Xuan, CEO of Yuanxin Huibao, expressed optimism that this partnership would greatly improve access to CAR-T treatments in Pakistan, benefiting a broader range of patients.